Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer
NCT00897533 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 137
Last updated 2017-05-19
Summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients respond to treatment with erlotinib.
PURPOSE: This laboratory study is developing a model to predict progression-free survival after erlotinib in patients with non-small cell lung cancer.
Conditions
Interventions
- GENETIC
-
gene mapping
- GENETIC
-
polymorphism analysis
- OTHER
-
diagnostic laboratory biomarker analysis
- OTHER
-
immunohistochemistry staining method
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
ECOG-ACRIN Cancer Research Group
lead NETWORK
Principal Investigators
-
Jill Kolesar, PharmD · University of Wisconsin, Madison
Eligibility
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-04-13
- Primary Completion
- 2008-04-13
- Completion
- 2008-04-13
More Related Trials
-
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
NCT00567359 ·Status: COMPLETED ·Phase: PHASE2
-
Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients
NCT04912687 ·Status: COMPLETED ·Phase: NA
-
Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer
NCT00579683 ·Status: COMPLETED
-
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression
NCT02431169 ·Status: TERMINATED
-
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
NCT01250119 ·Status: COMPLETED ·Phase: PHASE2
-
Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer
NCT01967095 ·Status: COMPLETED ·Phase: PHASE1
-
Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer
NCT02169349 ·Status: COMPLETED
-
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
NCT01189435 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
NCT03292133 ·Status: TERMINATED ·Phase: PHASE2
-
Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung
NCT01013831 ·Status: TERMINATED ·Phase: PHASE1
-
Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib
NCT00815971 ·Status: UNKNOWN
-
STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE
NCT02328391 ·Status: UNKNOWN
-
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.
NCT00773383 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
NCT01310036 ·Status: COMPLETED ·Phase: PHASE2
-
Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)
NCT02293733 ·Status: COMPLETED
-
A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
NCT00830245 ·Status: TERMINATED ·Phase: PHASE2
-
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
NCT02770014 ·Status: TERMINATED ·Phase: PHASE2
-
Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
NCT00085839 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
NCT00988169 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test
NCT02738684 ·Status: UNKNOWN
-
Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
NCT00989690 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
NCT01221077 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
NCT03392246 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
NCT01260181 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy
NCT00452075 ·Status: TERMINATED ·Phase: PHASE2